A Phase 3 interventional study of Lamotrigine in Mood Disorders, sponsored by GlaxoSmithKline. Completed at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-16.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 269 studies in Mood Disorders with a site in United States — 37 open to participants now, 44 under way, 2 of them phase 3. Mood Disorders · United States.
Among the 269 studies in Mood Disorders with a site in United States, this one is the 94th largest by enrollment of the 210 interventional ones that give a count, is one of 12 that started in 2008, is one of 16 in phase 3, and was the 69th registered.
562 studies on the registry are indexed under Mood Disorders; 106 are open to participants now.
Browse Mood Disorders studies →37 of the 269 studies in Mood Disorders with a site in United States are open now. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–45 · Women only
Eli Lilly and Company · Sites in United States, Australia, Brazil and 12 more countries
Ages 18–75
University of California, Berkeley · Sites in United States
Ages 18–90 · Healthy volunteers
Stanford University · Sites in United States
Ages 5–14
Ksana Health · Sites in United States
Ages 13–24
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 78 Mood Disorders studies recruiting now, 21 (27%) set no upper age limit and 46 (59%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
269 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 61 · Phase 3 22 · Phase 4 19
First in 1979; this study’s year is marked. 12 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 97 is above the median of 80 across 420 interventional studies indexed under Mood Disorders.
Median enrollment 81 across the 210 interventional studies, 212 across the 58 observational. Of the 213 that completed or were terminated, 77 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 269 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 2 studies filed under Mood Disorders — fewer than ten, so there is no comparison to draw.
16 of the studies in Mood Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07676110soundBrilliance LLCThe Impact of Enhanced Music & Natural Visuals on Emotional Health | 2026-12 |
| NCT05767593Massachusetts General HospitalClinical Validation of Samsung Smartwatch | 2026-12-01 |
| NCT05658796University of PittsburghRXWell to Decrease Post-Operative Opioid Use in Total Knee or Hip Arthroplasty | 2026-12-01 |
| NCT05282277University of North Carolina, Chapel HillExamining the Effects of Estradiol on Neural and Molecular Response to Reward | 2026-12-31 |
| NCT05920252Ksana HealthA Digitally Assisted Risk Reduction Platform for Youth at High Risk for Suicide | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 269 studies in Mood Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the convenience and satisfaction of new orally disintegrating tablet formulation (ODT) of lamictal in subjects with a mood disorder. This was a multicenter, open-label study in participants with a mood disorder, who reported difficulty or discomfort in swallowing the currently marketed IR compressed tablet formulation of lamotrigine and who had a person (such as a spouse, partner, companion, aid, nurse, caregiver, etc) willing to complete a Companion/Caregiver Question. Subjects were switched from the currently marketed lamotrigine IR formulation to a matching dose of lamotrigine IR orally disintegrating tablet (ODT) for 3 weeks to determine convenience and satisfaction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If female, the subject is eligible to enter and participate in this study if she is not lactating and is of:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lamictal orally disintegrating tablet (ODT)
Drug: Lamotrigine
Experimental formulation
Mean Change From Baseline in the Convenience Subscale Score (CSS) Derived From the Treatment Satisfaction Questionnaire for Medication (TSQM v 1.4) Using Items 9 (Ease of Use), 10 (Ease of Planning to Use), and 11 (Convenience) at Week 3.
The CSS is the sum of items 9 (values: 1=Extremely difficult - 7=Extremely easy), 10 (same set of values as for 9), and 11 (1=Extremely inconvenient - 7=Extremely convenient). The sum has 3 subtracted from it, is divided by 18, and then multiplied by 100; the range is 0-100. Change from baseline=end of study CSS minus baseline score.
Time frame: Baseline, End of Study (Week 3) or Early Withdrawal
Mean Change From Baseline in the Global Satisfaction Subscale Score, From the TSQM Using Items 12 (Confidence in Medicine), 13 (Certainty That Good Things About Medication Outweigh Bad Things), and 14 (Satisfaction With Medication) at Week 3
The Global Satisfaction Subscale Score is the sum of item 12 (values: 1=Not at all confident - 5=Extremely confident), item 13 (values: 1=Not at all certain - 5=Extremely certain), and item 14 (Extremely dissatisfied - 7=Extremely satisfied). The sum has 3 subtracted from it, is divided by 14, and then multiplied by 100; thus, the range is 0-100.
Time frame: Baseline, End of Study (Week 3) or Early Withdrawal
Mean Change From Baseline in Clinical Global Impression of Illness-Severity at Week 3
Clinician assessment evaluating how mentally ill the patient is at time of evaluation. The questionnaire is based on a 7-point scale (from1 = Normal to 7 = Among the most extremely ill patients).
Time frame: Baseline, End of Study (Week 3) or at Early Withdrawal
Mean Change From Baseline in the Beck Depression Inventory (BDI-II) Score at Week 3
Participant-reported questionnaire consisting of 21 items on a 4 point scale (0 to 3, with 3 indicating most severely ill), with the score being the sum of the items. The change from baseline is the end of study score minus the baseline score; larger values indicate more depression with the ODT formulation relative to the IR formulation.
Time frame: Baseline, End of Study (Week 3 weeks) or at Early Withdrawal
Number of Participants Answering the Question "Did the Tablets Dissolve Instantly (Yes or no)?" at Week 3
The Organoleptic Questionnaire (9 items) was used to assess the participants' satisfaction with the physical characteristics of the ODT formulation e.g. rate of dissolution, flavor. Question number 1 on organoleptic questionnaire: Did the tablets dissolve instantly (yes or no)?
Time frame: End of Study (Week 3) or Early Withdrawal
Number of Participants Answering the Question "How Satisfied or Dissatisfied Were You With the Time it Took the Tablet to Dissolve" at Week 3
Question number 2 on organoleptic questionnaire: How satisfied or dissatisfied were you with the time it took the tablet to dissolve? \[from a rating of 1 (Extremely dissatisfied) to 5 (Extremely satisfied)\]
Time frame: Baseline, End of Study (Week 3) or Early Withdrawal
Number of Participants Answering the Question "How Did the Dissolved Tablet Feel in Your Mouth?" at Week 3
Question number 3 on organoleptic questionnaire: How did the dissolved tablet feel in your mouth? \[from a rating of 1 (Extremely gritty) to 5 (Extremely smooth)\]
Time frame: End of Study (Week 3) or Early Withdrawal
Number of Participants Answering the Question "How Satisfied Were You With the Flavor of the Tablet?" at Week 3
Question number 4 on organoleptic questionnaire: How satisfied were you with the flavor of the tablet? \[from a rating of 1 (Extremely dissatisfied) to 5 (Extremely satisfied)\]
Time frame: End of Study (Week 3) or Early Withdrawal
Number of Participants Answering the Question "How Would You Rate the Strength of the Flavor of the Tablet"? at Week 3
Organoleptic Questionnaire, question 5: How would you rate the strength of the flavor of the tablet? \[from 1 a rating of (Extremely bothersome) to 5 (Extremely pleasant)\]
Time frame: End of Study (Week 3) or Early Withdrawal
Number of Participants Answering the Question "How Would You Rate the Aftertaste of the Tablet"? at Week 3.
Organoleptic Questionnaire, question 6: How would you rate the aftertaste of the tablet (the taste remaining in your mouth after swallowing the tablet)? \[from a rating of 1 (Extremely bothersome) to 6 (Did NOT experience an aftertaste)\]
Time frame: End of Study (Week 3) or Early Withdrawal
Number of Participants Answering the Question "How Satisfied Were You With the Aftertaste of the Tablet"? at Week 3
Organoleptic Questionnaire, question 7: How satisfied were you with the aftertaste of the tablet (the taste remaining in your mouth after swallowing the tablet)? \[from a rating of 1 (Extremely dissatisfied) to 6 (I did NOT experience an aftertaste)\]
Time frame: Baseline, End of Study (Week 3) or Early Withdrawal
Number of Participants Answering the Question "Compared to Standard Tablets That Need to be Swallowed With Liquid, How Convenient or Inconvenient Did You Find This Orally Disintegrating Tablet"? at Week 3
Organoleptic Questionnaire, question 8: Compared to standard tablets that need to be swallowed with liquid, how convenient or inconvenient did you find this orally disintegrating tablet? (from a rating of 1 \[Extremely inconvenient\] to 5 \[Extremely convenient\])
Time frame: End of Study (Week 3) or at Early Withdrawal
Number of Participants Answering the Question "Compared to Standard Tablets That Need to be Swallowed With Liquid, How Easy or Difficult is it to Use This Orally Disintegrating Tablet?" at Week 3
Organoleptic Questionnaire, question 9: Compared to standard tablets that need to be swallowed with liquid, how easy or difficult is it to use this orally disintegrating tablet? \[from a rating of 1 (Extremely difficult) to 5 (Extremely easy)\]
Time frame: End of Study (Week 3) or at Early Withdrawal
Number of Participants Indicating a Preference for ODT or the Standard IR Tablet at Week 3
Participant indicated whether preference was for ODT or the standard IR tablet
Time frame: End of Study (Week 3) or at Early Withdrawal
Number of Companions/Caregivers Indicating Whether ODT or Standard IR Tablet is More Convenient at Week 3
Companion/Caregiver indicates whether ODT is more convenient or standard IR tablet is more convenient
Time frame: End of Study (Week 3) or at Early Withdrawal
Number of Participants Indicating at Week 3 (by Answering Yes/no) That They Would be More Likely to Take the ODT Formulation
Tablet Routine Questionnaire (Adherence): Adherence to the treatment was evaluated by asking if the participant would be more likely to take the ODT formulation (yes/no)
Time frame: End of Study (Week 3) or at Early Withdrawal
| Milestone | Lamotrigine |
|---|---|
| Started | 97 |
| Completed | 89 |
| Not completed | 8 |
| Withdrew: Adverse event | 4 |
| Withdrew: Protocol violation | 4 |
The CSS is the sum of items 9 (values: 1=Extremely difficult - 7=Extremely easy), 10 (same set of values as for 9), and 11 (1=Extremely inconvenient - 7=Extremely convenient). The sum has 3 subtracted from it, is divided by 18, and then multiplied by 100; the range is 0-100. Change from baseline=end of study CSS minus baseline score.
| Points on a subscale | Lamotrigine |
|---|---|
| Mean Change From Baseline in the Convenience Subscale Score (CSS) Derived From the Treatment Satisfaction Questionnaire for Medication (TSQM v 1.4) Using Items 9 (Ease of Use), 10 (Ease of Planning to Use), and 11 (Convenience) at Week 3. | 23.3 ± 22.5 |
The Global Satisfaction Subscale Score is the sum of item 12 (values: 1=Not at all confident - 5=Extremely confident), item 13 (values: 1=Not at all certain - 5=Extremely certain), and item 14 (Extremely dissatisfied - 7=Extremely satisfied). The sum has 3 subtracted from it, is divided by 14, and then multiplied by 100; thus, the range is 0-100.
| Points on a subscale | Lamotrigine |
|---|---|
| Mean Change From Baseline in the Global Satisfaction Subscale Score, From the TSQM Using Items 12 (Confidence in Medicine), 13 (Certainty That Good Things About Medication Outweigh Bad Things), and 14 (Satisfaction With Medication) at Week 3 | -0.3 ± 29.34 |
Clinician assessment evaluating how mentally ill the patient is at time of evaluation. The questionnaire is based on a 7-point scale (from1 = Normal to 7 = Among the most extremely ill patients).
| Points on a scale | Lamotrigine |
|---|---|
| Mean Change From Baseline in Clinical Global Impression of Illness-Severity at Week 3 | 0.0 ± 0.81 |
Participant-reported questionnaire consisting of 21 items on a 4 point scale (0 to 3, with 3 indicating most severely ill), with the score being the sum of the items. The change from baseline is the end of study score minus the baseline score; larger values indicate more depression with the ODT formulation relative to the IR formulation.
| Points on a scale | Lamotrigine |
|---|---|
| Mean Change From Baseline in the Beck Depression Inventory (BDI-II) Score at Week 3 | -1.7 ± 9.52 |
The Organoleptic Questionnaire (9 items) was used to assess the participants' satisfaction with the physical characteristics of the ODT formulation e.g. rate of dissolution, flavor. Question number 1 on organoleptic questionnaire: Did the tablets dissolve instantly (yes or no)?
| Number of participants | Lamotrigine |
|---|---|
| Yes | 60 |
| No | 37 |
Question number 2 on organoleptic questionnaire: How satisfied or dissatisfied were you with the time it took the tablet to dissolve? \[from a rating of 1 (Extremely dissatisfied) to 5 (Extremely satisfied)\]
| Number of participants | Lamotrigine |
|---|---|
| Extremely dissatisfied | 3 |
| Very dissatisfied | 10 |
| Satisfied | 37 |
| Very satisfied | 18 |
| Extremely satisfied | 29 |
Question number 3 on organoleptic questionnaire: How did the dissolved tablet feel in your mouth? \[from a rating of 1 (Extremely gritty) to 5 (Extremely smooth)\]
| Number of participants | Lamotrigine |
|---|---|
| Extremely gritty | 0 |
| Very gritty | 19 |
| Smooth | 45 |
| Very smooth | 19 |
| Extremely smooth | 14 |
Question number 4 on organoleptic questionnaire: How satisfied were you with the flavor of the tablet? \[from a rating of 1 (Extremely dissatisfied) to 5 (Extremely satisfied)\]
| Number of participants | Lamotrigine |
|---|---|
| Extremely dissatisfied | 5 |
| Very dissatisfied | 10 |
| Satisfied | 26 |
| Very satisfied | 23 |
| Extremely satisfied | 33 |
Organoleptic Questionnaire, question 5: How would you rate the strength of the flavor of the tablet? \[from 1 a rating of (Extremely bothersome) to 5 (Extremely pleasant)\]
| Number of participants | Lamotrigine |
|---|---|
| Extremely bothersome | 2 |
| Very bothersome | 14 |
| Pleasant | 36 |
| Very pleasant | 22 |
| Extremely pleasant | 23 |
Organoleptic Questionnaire, question 6: How would you rate the aftertaste of the tablet (the taste remaining in your mouth after swallowing the tablet)? \[from a rating of 1 (Extremely bothersome) to 6 (Did NOT experience an aftertaste)\]
| Number of participants | Lamotrigine |
|---|---|
| Extremely bothersome | 4 |
| Very bothersome | 20 |
| Pleasant | 25 |
| Very pleasant | 7 |
| Extremely pleasant | 12 |
| I did NOT experience an aftertaste | 29 |
Organoleptic Questionnaire, question 7: How satisfied were you with the aftertaste of the tablet (the taste remaining in your mouth after swallowing the tablet)? \[from a rating of 1 (Extremely dissatisfied) to 6 (I did NOT experience an aftertaste)\]
| Number of participants | Lamotrigine |
|---|---|
| Extremely dissatisfied | 3 |
| Very dissatisfied | 16 |
| Satisfied | 28 |
| Very satisfied | 11 |
| Extremely satisfied | 11 |
| I did NOT experience an aftertaste | 28 |
Organoleptic Questionnaire, question 8: Compared to standard tablets that need to be swallowed with liquid, how convenient or inconvenient did you find this orally disintegrating tablet? (from a rating of 1 \[Extremely inconvenient\] to 5 \[Extremely convenient\])
| Number of participants | Lamotrigine |
|---|---|
| Extremely inconvenient | 8 |
| Very inconvenient | 9 |
| Convenient | 16 |
| Very convenient | 17 |
| Extremely convenient | 47 |
Organoleptic Questionnaire, question 9: Compared to standard tablets that need to be swallowed with liquid, how easy or difficult is it to use this orally disintegrating tablet? \[from a rating of 1 (Extremely difficult) to 5 (Extremely easy)\]
| Number of participants | Lamotrigine |
|---|---|
| Extremely difficult | 2 |
| Very difficult | 3 |
| Easy | 17 |
| Very easy | 20 |
| Extremely easy | 55 |
Participant indicated whether preference was for ODT or the standard IR tablet
| Number of participants | Lamotrigine |
|---|---|
| Prefer ODT | 72 |
| Prefer standard IR tablet | 25 |
Companion/Caregiver indicates whether ODT is more convenient or standard IR tablet is more convenient
| Number of participants | Lamotrigine |
|---|---|
| ODT more convenient | 79 |
| Standard IR tablet more convenient | 18 |
Tablet Routine Questionnaire (Adherence): Adherence to the treatment was evaluated by asking if the participant would be more likely to take the ODT formulation (yes/no)
| Number of participants | Lamotrigine |
|---|---|
| Yes | 84 |
| No | 10 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lamotrigine | — | 1/97 (1%) | 28/97 (28.9%) |
| Event | Lamotrigine |
|---|---|
| Myocardial infarctionCardiac disorders | 1/97 |
| Event | Lamotrigine |
|---|---|
| HeadacheNervous system disorders | 5/97 |
| AnxietyPsychiatric disorders | 3/97 |
| DepressionPsychiatric disorders | 3/97 |
| HypomaniaPsychiatric disorders | 3/97 |
| NauseaGastrointestinal disorders | 2/97 |
| Depressed moodPsychiatric disorders | 1/97 |
| InsomniaPsychiatric disorders | 1/97 |
| RestlessnessPsychiatric disorders | 1/97 |
| Suicidal ideationPsychiatric disorders | 1/97 |
| DizzinessNervous system disorders | 1/97 |
| Age, Continuous(years) | Lamotrigine |
|---|---|
| Mean | 41.0 ± 12.07 |
| Gender(Participants) | Lamotrigine |
|---|---|
| Female | 83 |
| Male | 14 |
| Race/Ethnicity, Customized(participants) | Lamotrigine |
|---|---|
| White | 94 |
| Black | 2 |
| Mixed race | 1 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Jan 2008, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lamotrigine